PLATFORM TECHNOLOGIES

PYC uses RNA therapeutics to increase gene expression in haploinsufficient diseases, using a proprietary delivery technology to reach target cells.1
An image of two female scientists wearing white lab coats, blue gloves and clear goggles standing side-by-side. The scientist on the left is reaching upwards and pressing a button on a large machine. The scientist on the right is watching while holding a rectangular box.

PYC designs RNA therapies to increase gene expression

There are two copies of every gene in humans

In haploinsufficient diseases, one copy of a gene is non-functional

PYC’s drug candidates leverage the ‘good’ copy of the gene to restore expression

RNA therapeutics are precision medicines that modify protein production to restore healthy cell function

PYC’s superior drug delivery technology

PYC combines this precision drug design expertise with its delivery technology to harness a new class of RNA therapeutic. 1

 Commercialised RNA treatments have been restricted by their poor uptake into the target cell as a result of their size and molecular structure. This ‘delivery challenge’ has limited the number of diseases for which RNA therapies have been successfully created.

 By binding our custom RNA therapies with our proprietary therapeutic delivery platform of cell-penetrating peptides (CPPs), we are able to solve this therapeutic challenge to provide targeted treatments to a wider range of diseases.

Footnotes

  1. PYC’s drug candidate for PMS (PYC-002) does not use a delivery peptide due to the clinical validation of ‘naked’ oligonucleotides in the Central Nervous System ↩︎